Literature DB >> 15919201

Guanylyl cyclase C as a reliable immunohistochemical marker and its ligand Escherichia coli heat-stable enterotoxin as a potential protein-delivering vehicle for colorectal cancer cells.

E Buc1, M Der Vartanian, C Darcha, P Déchelotte, D Pezet.   

Abstract

mRNA-based technologies and preclinical research in a variety of animal models have shown that guanylyl cyclase C (GCC) is a highly sensitive and specific molecular marker for the diagnosis of colorectal cancer (CRC). GCC is also a receptor for Escherichia coli (E. coli) heat-stable enterotoxin (STa) and can be used for STa-directed delivery of small-sized imaging agents to human CRC tumours. In this study, we have evaluated GCC as a new immunohistochemical (IHC) marker for CRC tissues and STa as a suitable vector for delivering high-sized protein molecules to CRC cells. Firstly, we have developed a highly sensitive EnVision(+)-based IHC staining method for detecting GCC in serial paraffin-embedded sections of primary and metastatic CRC (38 cases) or non-CRC (14 cases) adenocarcinomas. Carcinoembryonic antigen (CEA) and cytokeratin 20 (CK20) were chosen as controls. Our results indicate that GCC staining was positive in 100% of CRC tumours and was comparable to CEA (95%) or CK20 (92%). In contrast to CEA and CK20, GCC was negative in all of the extra-intestinal non-CRC tumours examined. GCC appears to display higher specificity than either CEA or CK20 while retaining high sensitivity, suggesting that it is a better CRC marker than CEA or CK20. Secondly, STa was genetically coupled to green fluorescent protein (GFP) and the resulting GFP-tagged STa was characterized for expression in E. coli and enterotoxicity in mouse. The binding characteristics of GFP-STa in CRC Caco-2 cells were followed by immunofluorescence microscopy. In this work we show that GFP-tagged STa is biologically active and has retained its ability to internalise into Caco-2 cells making it a potential vehicle for the delivery of anticancer therapeutic protein agents.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15919201     DOI: 10.1016/j.ejca.2005.02.031

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  8 in total

1.  A phase II study of antibody-drug conjugate, TAK-264 (MLN0264) in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing guanylyl cyclase C.

Authors:  Khaldoun Almhanna; David Wright; Teresa Macarulla Mercade; Jean-Luc Van Laethem; Antonio Cubillo Gracian; Carmen Guillen-Ponce; Jason Faris; Carolina Muriel Lopez; Richard A Hubner; Johanna Bendell; Alain Bols; Jaime Feliu; Naureen Starling; Peter Enzinger; Devalingham Mahalingham; Wells Messersmith; Huyuan Yang; Adedigbo Fasanmade; Hadi Danaee; Thea Kalebic
Journal:  Invest New Drugs       Date:  2017-05-19       Impact factor: 3.850

2.  Receptor guanylyl cyclase C (GC-C): regulation and signal transduction.

Authors:  Nirmalya Basu; Najla Arshad; Sandhya S Visweswariah
Journal:  Mol Cell Biochem       Date:  2009-12-04       Impact factor: 3.396

3.  Pathogen specific, IRF3-dependent signaling and innate resistance to human kidney infection.

Authors:  Hans Fischer; Nataliya Lutay; Bryndís Ragnarsdóttir; Manisha Yadav; Klas Jönsson; Alexander Urbano; Ahmed Al Hadad; Sebastian Rämisch; Petter Storm; Ulrich Dobrindt; Ellaine Salvador; Diana Karpman; Ulf Jodal; Catharina Svanborg
Journal:  PLoS Pathog       Date:  2010-09-23       Impact factor: 6.823

4.  Expression of the intestinal biomarkers Guanylyl cyclase C and CDX2 in poorly differentiated colorectal carcinomas.

Authors:  Brody Winn; Rosemarie Tavares; Andres Matoso; Lelia Noble; Jacqueline Fanion; Scott A Waldman; Murray B Resnick
Journal:  Hum Pathol       Date:  2009-10-01       Impact factor: 3.466

Review 5.  Bacterial heat-stable enterotoxins: translation of pathogenic peptides into novel targeted diagnostics and therapeutics.

Authors:  Jieru E Lin; Michael Valentino; Glen Marszalowicz; Michael S Magee; Peng Li; Adam E Snook; Brian A Stoecker; Chang Chang; Scott A Waldman
Journal:  Toxins (Basel)       Date:  2010-08-05       Impact factor: 4.546

6.  TAK-264 (MLN0264) in Previously Treated Asian Patients with Advanced Gastrointestinal Carcinoma Expressing Guanylyl Cyclase C: Results from an Open-Label, Non-randomized Phase 1 Study.

Authors:  Yung-Jue Bang; Toshimi Takano; Chia-Chi Lin; Adedigbo Fasanmade; Huyuan Yang; Hadi Danaee; Takayuki Asato; Thea Kalebic; Hui Wang; Toshihiko Doi
Journal:  Cancer Res Treat       Date:  2017-05-10       Impact factor: 4.679

7.  Single Chain Variable Fragments Produced in Escherichia coli against Heat-Labile and Heat-Stable Toxins from Enterotoxigenic E. coli.

Authors:  Christiane Y Ozaki; Caio R F Silveira; Fernanda B Andrade; Roberto Nepomuceno; Anderson Silva; Danielle D Munhoz; Bruno B Yamamoto; Daniela Luz; Patrícia A E Abreu; Denise S P Q Horton; Waldir P Elias; Oscar H P Ramos; Roxane M F Piazza
Journal:  PLoS One       Date:  2015-07-08       Impact factor: 3.240

8.  A monomethyl auristatin E-conjugated antibody to guanylyl cyclase C is cytotoxic to target-expressing cells in vitro and in vivo.

Authors:  Melissa Gallery; Julie Zhang; Daniel P Bradley; Pamela Brauer; Donna Cvet; Jose Estevam; Hadi Danaee; Edward Greenfield; Ping Li; Mark Manfredi; Huay-Keng Loke; Claudia Rabino; Brad Stringer; Mark Williamson; Tim Wyant; Johnny Yang; Qing Zhu; Adnan Abu-Yousif; O Petter Veiby
Journal:  PLoS One       Date:  2018-01-25       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.